In summary, our study underscores the importance of leukemia subtype classification, characterization of IKZF1 alterations, and genomics-based analysis of cooperating lesions, in predicting the prognosis of pediatric patients with B-ALL undergoing MRD-directed therapy. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.